Reuters logo
3 个月前
BRIEF-Biohaven's Trigriluzole receives fast track designation from U.S. FDA
2017年5月15日 / 上午9点04分 / 3 个月前

BRIEF-Biohaven's Trigriluzole receives fast track designation from U.S. FDA

May 15 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd

* Biohaven's trigriluzole receives fast track designation from U.S. FDA

* Currently conducting a phase 2/3 clinical trial in patients with sca, with topline results expected in 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below